ReviewThe Lancet. Infectious diseases2026
Innovation in active and passive immunisation of people who are immunocompromised: a call to action.
Review in The Lancet. Infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- The Vaccine Candidates Against Major Fish Pathogens (Life (Basel, Switzerland) · 2026Article
- Monoclonal antibody CIS43LS sets the bar for long-acting malaria protection.The Journal of clinical investigation · 2026Article
- Prevention of neuroinfectious-diseases: high impact of vaccination programs - but the potential is not maxed out yet.Neurological research and practice · 2026Review
- Review of Infections in Immunocompromised Travellers: Epidemiology, Infection Prevention and Management.Microorganisms · 2026Review
- Design, synthesis, and biological evaluation of 2-phenylthiazole CYP51 inhibitors.RSC medicinal chemistry · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The proportion of the population with immunocompromising conditions, who are at increased risk for complications from infectious diseases, continues to grow. Concurrently, outbreaks due to known and emerging pathogens are increasing. Vaccines are the foundation of infection prevention; however, attenuated immune responses in people who are immunocompromised necessitates innovation in design and delivery strategies. Passive immunisation, whereby the desired immunity is directly transferred to an individual, albeit transiently, could be valuable for patients who are unable to generate robust immune responses with vaccination or infection. However, existing therapies are insufficient. Considerable technical and conceptual advancements in the field of immunology have created unprecedented opportunities for the development of novel strategies and therapies to prevent and treat infectious diseases, and studies in people who are immunocompromised are an important setting in which to apply these developments. In this Series paper, we consider key unmet needs in the areas of vaccinology, monoclonal antibody design, study endpoints, health systems approaches, and policy considerations for people who are immunocompromised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.